COENZYME Q10 IN HUNTINGTON'S DISEASE (2 CARE)

辅酶 Q10 在亨廷顿病中的应用（2 护理）

• 批准号: 7951404
• 负责人: FRANCIS O WALKER
• 金额: $ 2.58万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951404
• 关键词: Blood; Caring; Chronic; Clinical Research; Coenzyme Q10; Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Grant; Huntington Disease; Institution; Placebos; Population; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; dosage; functional decline

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives: To assess the effects of chronic CoQ treatment in slowing the functional decline of subjects with HD, as determined by the Unified Huntington's Disease Rating Scale (UHDRS). To assess the blood levels of CoQ at the studied dosages. Secondary Objective: To examine the long term safety and tolerability of CoQ in the HD population. To compare subjects treated with CoQ with those treated with placebo with regard to changes from Baseline to Month 60 in other components of the UHDRS.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目标：评估慢性COQ治疗在减缓HD受试者功能下降的影响下，由统一的亨廷顿疾病评级量表（UHDRS）确定。评估研究剂量的COQ的血液水平。 次要目标：检查HD人群中COQ的长期安全性和耐受性。将与COQ治疗的受试者与安慰剂治疗的受试者在UHDRS的其他组件中从基线到60个月的变化进行比较。